Premium
Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms
Author(s) -
GudayolFerré Esteve,
HerreraGuzmán Ixchel,
Camarena Beatriz,
CortésPenagos Carlos,
HerreraAbarca Jorge E.,
MartínezMedina Patricia,
AsbunBojalil Juan,
LiraIslas Yuridia,
ReyesPonce Celia,
GuàrdiaOlmos Joan
Publication year - 2012
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2267
Subject(s) - fluoxetine , neuropsychology , medicine , depression (economics) , psychology , oncology , placebo , serotonergic , psychiatry , clinical psychology , serotonin , cognition , pathology , receptor , alternative medicine , economics , macroeconomics
Objective The aim of our work is to study the possible role of clinical variables, neuropsychological performance, and the 5HTTLPR, rs25531, and val108/58Met COMT polymorphisms on the prediction of depression remission after 12 weeks' treatment with fluoxetine. These variables have been studied as potential predictors of depression remission, but they present poor prognostic sensitivity and specificity by themselves. Methods Seventy‐two depressed patients were genotyped according to the aforementioned polymorphisms and were clinically and neuropsychologically assessed before a 12‐week fluxetine treatment. Results Only the La allele of rs25531 polymorphism and the GG and AA forms of the val 108/158 Met polymorphism predict major depressive disorder remission after 12 weeks' treatment with fluoxetine. None of the clinical and neuropsychological variables studied predicted remission. Conclusions Our results suggest that clinical and neuropsychological variables can initially predict early response to fluoxetine and mask the predictive role of genetic variables; but in remission, where clinical and neuropsychological symptoms associated with depression tend to disappear thanks to the treatment administered, the polymorphisms studied are the only variables in our model capable of predicting remission. However, placebo effects that are difficult to control require cautious interpretation of the results. Copyright © 2012 John Wiley & Sons, Ltd.